REG - Roquefort Theraptcs. - Issue of Warrants

Roquefort TherapeuticsAnnouncement

22/06/2022 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220622:nRSV8571Pa&default-theme=true

RNS Number : 8571P  Roquefort Therapeutics PLC  22 June 2022

22 June 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Issue of Warrants

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, announces
the following issue of warrants to recently appointed Non-Executive Directors
and an advisor to the Board:

 

                       Position                Number of Warrants Issued  Total Number of Warrants Held After Issue

 Name
 Ms Jean Duvall        Non-Executive Director  300,000                    300,000
 Dr Simon Sinclair(1)  Non-Executive Director  300,000                    300,000
 Prof. Trevor Jones    Board Advisor           300,000                    300,000

(1) Warrants held in the name of Livingstone Investment Holdings Ltd, a
company in which Dr Sinclair has a beneficial interest

 

The warrants have been issued in relation to the appointment of the abovenamed
earlier this year and form part of their annual remuneration package.

 

The warrants have a term of 5 years and are exercisable at a price of 15
pence, with 50% exercisable after 12 months and the balance exercise after 24
months.

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is a pre-clinical biotech company
focused on developing first in class Midkine targeting drugs for the treatment
of cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018, as amended ("UK MAR").

The notifications below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Jean Duvall
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Director
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrants (exercise price of 15 pence)

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Issue of warrants
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  15 pence per share           300,000
 d   Aggregated information

     - Aggregated volume                                          -       300,000

     - Price                                                      -       15p
 e)  Date of the transactions                                     22 June 2022
 f)  Place of the transactions                                    Outside a trading venue

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Simon Sinclair
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Director
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Warrants (exercise price of 15 pence)

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Issue of warrants
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  15 pence per share           300,000
 d   Aggregated information

     - Aggregated volume                                          -       300,000

     - Price                                                      -       15p
 e)  Date of the transactions                                     22 June 2022
 f)  Place of the transactions                                    Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDZGZVKZGGZZM